Related Experiment Videos
The molecular markers of hemostatic activation on coronary artery disease
1Genetic and Teratology Research Center, Istanbul University, Cerrahpaşa Medical Faculty, Turkey.
Insights
Patients with coronary artery disease exhibit heightened blood coagulability. Molecular markers of hemostasis, including lipoprotein (a) and D-dimer, are significantly elevated, underscoring their clinical importance in assessing disease risk.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Clinical Biochemistry
Background:
- Hemostasis involves endothelial cells, platelets, and coagulation/fibrinolytic proteins.
- Elevated molecular markers indicate hemostatic system activation.
- Coronary artery disease (CAD) is associated with altered hemostatic balance.
Purpose of the Study:
- To investigate serum lipoprotein (a) and plasma markers in patients with coronary artery disease.
- To compare marker levels between CAD patients and a control group.
- To assess the clinical utility of these molecular markers in CAD.
Main Methods:
- Measurement of serum lipoprotein (a).
- Quantification of plasma markers: platelet factor 4, beta-thromboglobulin, thrombin-antithrombin complex, fibrinopepdide A, D-dimer, tissue plasminogen activator, tissue plasminogen activator inhibitor, and fibronectin.
- Comparison of marker levels between CAD patients and healthy controls.
Main Results:
- All investigated molecular markers were significantly higher in CAD patients compared to controls.
- Elevated levels indicate increased activation of the hemostatic system in CAD.
- Lipoprotein (a) and D-dimer showed significant increases.
Conclusions:
- Patients with coronary artery disease demonstrate increased blood coagulability.
- Molecular markers are valuable indicators of hemostatic alterations in CAD.
- These markers hold significant importance in clinical practice for CAD assessment.
Abstract:
Endothelial cells, circulating platelets, and proteins of the coagulation and fibrinolytic systems are known to contribute to the hemostatic processes. Various molecular markers of hemostatic alteration are found in increased amounts in the circulation during the activation of this process. In this study, we investigated serum lipoprotein (a) and plasma platelet factor 4, beta-thromboglobulin, thrombin-anthithrombin complex, fibrinopeptid A, D-dimer, tissue plasminogen activator, tissue plasminogen activator inhibitor, and fibronectin levels in patients with coronary artery disease. The levels of all these markers were found to be significantly higher as compared to the control group. Our findings suggest that patients with coronary artery disease have greater blood coagulability than controls, and the use of molecular markers has become greatly important in clinical practice.